Cdk4-inhibitor induces tumor regression of Bladder cancer in vivo using a metastatic mouse model

Cdk4/6 inhibitors have shown to increase overall survival in hormone-positive breast tumors, but whether other solid tumors could respond to these inhibitors has not yet defined. Here we show that Palbociclib (a Cdk4/6 specific inhibitor in clinic use) + cisplatin (CDDP, a chemotherapeutic agent most active in locally or advanced bladder cancer patients) treatment exerts antiproliferative effects in vivo using a bladder cancer mouse model. Gene expression was compared between normal bladders from transgenic CKO mice (Rbf/f, Ptenf/f, Tp53f/f, p107-/- ), tumor bladders from CKO inoculated with Adeno-Cre in the bladder, bladders from CKO treated with Cdk4-inhibitor+CDDP, and metastasis from these mice.